Shailaja Kasibhatla

Statistics

Publications

Citations

H-Index

Active since

1992

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

La Jolla Institute for Immunology

Maxim Integrated (United States)

Myriad Genetics

Novartis (Switzerland)

Shailaja Kasibhatla is an author at Genomics Institute of the Novartis Research Foundation specializing in apoptosis, life sciences, and pharmacology.

Publications per year

1992–2024

Publications

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text

Medicine, Oncology, Pharmacology +15

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Jun Liu, Shifeng Pan, Mindy H. Hsieh et al. · Proceedings of the National Academy of Sciences · 2013 · 835 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

DNA Damaging Agents Induce Expression of Fas Ligand and Subsequent Apoptosis in T Lymphocytes via the Activation of NF-κB and AP-1

Shailaja Kasibhatla, Thomas Brunner, Laurent Genestier et al. · Molecular Cell · 1998 · 727 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Acridine Orange/Ethidium Bromide (AO/EB) Staining to Detect Apoptosis

Shailaja Kasibhatla, Gustavo P. Amarante‐Mendes, Deborah Finucane et al. · Cold Spring Harbor Protocols · 2006 · 539 citations

Life Sciences, Cell Biology, Molecular Biology +10

Why target apoptosis in cancer treatment?

Shailaja Kasibhatla, Ben Tseng · PubMed · 2003 · 354 citations

Medicine, Cancer Biology, Oncology +17

1–5 of 68